Abstract
Among patients with atherothrombosis, including coronary artery disease (CAD), cerebrovascular disease (CVD), and peripheral arterial disease (PAD), patients with PAD generally have the worse prognosis. The Reduction of Atherothrombosis for Continued Health (REACH) Registry characterized the atherothrombotic risk factor profile, and evaluated treatment intensity and cardiovascular events among different atherothrombotic patient populations worldwide. Two thirds of PAD patients had polyvascular disease, defined as symptomatic involvement of more than one vascular bed. The risk factor profile in patients with CAD, CVD and PAD was very much similar. However, optimal risk factor control by medical treatment and lifestyle interventions was least accomplished in PAD patients. Furthermore, PAD patients and patients with polyvascular disease showed the highest cardiovascular event rates. Of note, therapeutic strategies are similar for all atherothrombotic disease categories, irrespective of the presence of polyvascular disease. Therefore, it is of the utmost importance to achieve optimal risk factor control, particularly for PAD patients and for those with polyvascular disease, in order to prevent future cardiovascular events.
Keywords: Cardiovascular events, guideline, peripheral arterial disease, risk factors, treatment
Current Vascular Pharmacology
Title:Lessons from the REACH Registry in Europe
Volume: 10 Issue: 6
Author(s): Tabita M. Valentijn and Robert J. Stolker
Affiliation:
Keywords: Cardiovascular events, guideline, peripheral arterial disease, risk factors, treatment
Abstract: Among patients with atherothrombosis, including coronary artery disease (CAD), cerebrovascular disease (CVD), and peripheral arterial disease (PAD), patients with PAD generally have the worse prognosis. The Reduction of Atherothrombosis for Continued Health (REACH) Registry characterized the atherothrombotic risk factor profile, and evaluated treatment intensity and cardiovascular events among different atherothrombotic patient populations worldwide. Two thirds of PAD patients had polyvascular disease, defined as symptomatic involvement of more than one vascular bed. The risk factor profile in patients with CAD, CVD and PAD was very much similar. However, optimal risk factor control by medical treatment and lifestyle interventions was least accomplished in PAD patients. Furthermore, PAD patients and patients with polyvascular disease showed the highest cardiovascular event rates. Of note, therapeutic strategies are similar for all atherothrombotic disease categories, irrespective of the presence of polyvascular disease. Therefore, it is of the utmost importance to achieve optimal risk factor control, particularly for PAD patients and for those with polyvascular disease, in order to prevent future cardiovascular events.
Export Options
About this article
Cite this article as:
M. Valentijn Tabita and J. Stolker Robert, Lessons from the REACH Registry in Europe, Current Vascular Pharmacology 2012; 10 (6) . https://dx.doi.org/10.2174/157016112803520774
DOI https://dx.doi.org/10.2174/157016112803520774 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Protective Effects of Anesthetics on the Spinal Cord
Current Pharmaceutical Design Vascular Effects of Estrogenic Menopausal Hormone Therapy
Reviews on Recent Clinical Trials Inflammatory Cells and Proteases in Abdominal Aortic Aneurysm and its Complications
Current Drug Targets A Clinical Perspective of Soluble Epoxide Hydrolase Inhibitors in Metabolic and Related Cardiovascular Diseases
Current Molecular Pharmacology Matrix Metalloproteinase Inhibition in Atherosclerosis and Stroke
Current Molecular Medicine Gender as a Regulator of Atherosclerosis in Murine Models
Current Drug Targets ADAM17 as a Therapeutic Target in Multiple Diseases
Current Pharmaceutical Design Coronary Magnetic Resonance Imaging
Current Pharmaceutical Design Patent Selections
Recent Patents on Biomedical Engineering (Discontinued) Serum Biochemical Markers of Brain Injury
Mini-Reviews in Medicinal Chemistry Inflammation-Induced Thrombosis: Mechanisms, Disease Associations and Management
Current Pharmaceutical Design The Imaging of Apoptosis with the Radiolabelled Annexin A5: A New Tool in Translational Research
Current Clinical Pharmacology Thoracic Aortic Aneurysm: Blood Pressure and Inflammation as Key Factors in the Development of Aneurysm Dissection
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Medical Imaging Role of microRNAs on Blood Brain Barrier Dysfunction in Vascular Cognitive Impairment
Current Drug Delivery Editorial: microRNAs: Potential Targets for the Treatment of Cardiovascular Disease
Current Vascular Pharmacology Computer Aided Systems for Diabetic Retinopathy Detection Using Digital Fundus Images: A Survey
Current Medical Imaging Use of Diffusion-Weighted Magnetic Resonance Imaging and Apparent Diffusion Coefficient in Gastric Cancer Staging
Current Medical Imaging Closure of Patent Foramen Ovale: When and How?
Current Vascular Pharmacology Human Urotensin II Promotes Hypertension and Atherosclerotic Cardiovascular Diseases
Current Medicinal Chemistry